Option chain shows key data for Home Depot's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Home Depot.

Home Depot (NYSE:HD) Stock, Option Chain

Home Depot

nasdaq:aapl

NASDAQ:AMAT

nasdaq:amzn

NASDAQ:BCSI

nasdaq:csco

NASDAQ:EBAY

NASDAQ:FFIV

nasdaq:goog

NASDAQ:RVBD

NASDAQ:SNDK

NASDAQ:STX

NYSE:AA

nyse:ba

NYSE:CAT

NYSE:COF

nyse:dd

NYSE:FCX

NYSE:GS

NYSE:HD

NYSE:JPM

nyse:low

NYSE:LUV

NYSE:MS

NYSE:PNC

nyse:tol

NYSE:UNH

NYSE:UNP

NYSE:WEN

NYSE:WPO

Dow Shakes Off China Jitters; Techs Take Down Nasdaq

NYSE:RIO

Dow Trims Losses; Bears Keep Heat on Nasdaq

nyse:bp

Stocks Retreat Amid Chinese Worries

Mizuho analyst Vijay Rakesh maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Neutral and lowers the price target from $23 to $21.

News

Price Target

Analyst Ratings

INTC

Mizuho Maintains Neutral on Intel, Lowers Price Target to $21

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 400 points on Friday.
The Dow traded down 1.64% to 41,935.30 while the NASDAQ dipped 2.15% to 19,060.79. The S&amp;P 500 also fell, dropping, 1.77% to 5,813.73.
Check This Out: <a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Energy shares rose by 0.6% on Friday.
In trading on Friday, information technology shares tumbled by 2.1%.
Top Headline
On Friday, Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) reported better-than-expected first-quarter results.
The company posted quarterly sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the consensus of $37.28 billion, reflecting sales growth across all segments.
Adjusted EPS was 51 cents, down from 66 cents a year ago, beating the consensus of 37 cents, according to data from Benzinga Pro.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Conduit Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares shot up 52% to $0.12.</li>
<li>Shares of Vision Marine Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>)got a boost, surging 72% to $2.62 as it regained compliance with Nasdaq's minimum stockholders' equity requirement, which it previously failed to meet. Vision Marine partnered with Calip Group to produce advanced cooling plates for electric boat batteries.</li>
<li>DatChat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares were also up, gaining 107% to $6.63 after the company announced the pricing of a $5.1 million registered direct offering priced at-the-market under Nasdaq rules.</li>
</ul>
Equities Trading DOWN
<ul>
<li>IGM Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares dropped 69% to $1.94 &nbsp;after the company announced it is halting further development of Imvotamab and IGM-2644.</li>
<li>Shares of XTI Aerospace Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) were down 54% to $5.82. XTI Aerospace recently announced a $20 million offering of 363,636,364 shares at $0.055 per share.</li>
<li>22nd Century Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) was down, falling 39% to $4.97.</li>
</ul>
Commodities In commodity news, oil traded up 2.4% to $75.67 while gold traded up 1% at $2,716.70.
Silver traded up 1% to $31.315 on Friday, while copper fell 0.2% to $4.2995.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 0.79%, Germany's DAX 40 fell 0.44% and France's CAC 40 dipped 0.85%. Spain's IBEX 35 Index fell 1.43%, while London's FTSE 100 slipped 0.83%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 1.05%, China's Shanghai Composite Index dipping 1.33%, Hong Kong's Hang Seng Index declining 0.92% and India's BSE Sensex falling 0.31%.
Economics
<ul>
<li>Nonfarm payrolls rose by 256,000 last month, up from the downwardly revised 212,000 in November and sharply surpassing economist expectations of 160,000 payrolls as tracked by TradingEconomics.</li>
<li>The unemployment rate fell from 4.2% to 4.1%, beating forecasts of an unchanged reading.</li>
<li>Average hourly earnings rose 0.3% month-over-month in December, matching expectations but slowing from November's 0.4%. On a year-over-year basis, wages increased 3.9%, slightly below of the 4% forecast.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42873668/jim-cramer-lemonade-is-up-too-much-this-health-care-stock-can-go-lower">Jim Cramer: Lemonade Is &#8216;Up Too Much,&#8217; This Health Care Stock Can Go Lower</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

DATS

IGMS

VMAR

XTIA

XXII

Nasdaq Down Over 2%; Walgreens Posts Upbeat Results

Mizuho analyst Vijay Rakesh maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Outperform and lowers the price target from $130 to $110.

Mizuho Maintains Outperform on Seagate Tech Hldgs, Lowers Price Target to $110

Jefferies analyst Roger Song downgrades IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) from Buy to Hold and lowers the price target from $48 to $2.

Downgrades

Jefferies Downgrades IGM Biosciences to Hold, Lowers Price Target to $2

HC Wainwright &amp; Co. analyst Edward White maintains Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) with a Buy and raises the price target from $14 to $16.

INZY

HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Raises Price Target to $16

On Friday, Mersana Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) released initial data from the Phase 1 dose escalation and backfill cohorts <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42907652/mersana-therapeutics-announces-positive-initial-clinical-data-from-phase-1-clinical-trial-of-emilt" rel="noreferrer noopener">for emiltatug ledadotin</a>.
Emi-Le was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events reported.
At intermediate doses in the trial (38.1 mg/m2&nbsp;to 67.4 mg/m2), the confirmed objective response rate among evaluable patients was 23% (6 of 26 patients) across all B7-H4 high tumors and 23% (3 of 13 patients) with B7-H4 high TNBC, all of whom had previously been treated with at least one topo-1 ADC.
In the ASCENT Phase 3 trial of sacituzumab govitecan, the ORR with standard-of-care single-agent chemotherapy in relapsed/refractory TNBC was approximately 5%, with progression-free survival of approximately seven weeks.
Based on these encouraging Emi-Le data at intermediate doses, Mersana has advanced a dose of 67.4 mg/m2&nbsp;every four weeks into an expansion cohort in patients with TNBC who have received one to four prior treatment lines.
At high doses above 76 mg/m2, the confirmed ORR among evaluable patients was 22% (2 of 9) across all B7-H4 high tumors.
Additionally, 78% (7 of 9 patients) had ≥30% tumor reduction in target lesions.
At these high dose levels, objective responses in multiple evaluable patients with B7-H4 high tumors were not confirmed after protocol-mandated dose delays for proteinuria.
Mersana is implementing proteinuria mitigation efforts and continues to examine higher doses in dose escalation and backfill cohorts to identify a second dose for the expansion portion of the trial.
Concurrently, the FDA granted an additional Fast Track designation to Mersana Therapeutics&#8217; XMT-1660.
The company also announced that the World Health Organization has approved emiltatug ledadotin (abbreviated as Emi-Le) as XMT-1660&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42907717/mersana-therapeutics-announces-additional-fda-fast-track-designation-granted-to-emiltatug-ledadoti" rel="noreferrer noopener">international nonproprietary name</a>.
The new Fast Track designation is for advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 (HER2) low (IHC 1+ or IHC 2+/ISH–) or HER2-negative (IHC 0) disease, including triple-negative breast cancer (TNBC), who have received a prior topoisomerase-1 inhibitor ADC.
Additionally, hormone-receptor positive patients should also have received or be ineligible for endocrine therapy.
Price Action: MRSN stock is down 36.6% at $0.8245 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42917603/salesforce-empowers-retailers-with-ai-to-boost-efficiency-and-sales" target="_blank" rel="noreferrer noopener">Salesforce Launches Retail Cloud And Agentforce Solutions: Details</a></li>
</ul>
Photo via Shutterstock.

Biotech

Health Care

Movers

General

MRSN

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Unexpectedly strong labour market data has sparked a bearish response in crypto markets, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) teetering <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42913406/bitcoin-fights-to-regain-94000-what-does-technical-analysis-say">around the $94,000 mark</a>.
What Happened: Data published on Friday shows the U.S. <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42912480/us-economy-adds-256000-payrolls-in-december-as-tight-labor-market-tops-forecasts-dollar-treasury-yields-spike">added 256,000 parolls in December</a>, sending bond yields soaring and knocking Bitcoin off its morning recovery.
The apex crypto had recovered from $92,000 to $95,000 overnight, but quickly lost over $2,000 in reaction to the stronger-than-anticipated data. 
Crypto trader Jelle highlighted the abrupt shift in market sentiment, pointing out that the jobs data managed to reverse the price momentum with the words &#8220;stairs up, elevator down.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Job data here to mess things up, it was stairs up, elevator down after all &#x1f602;<a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/aPbsjXZ2rK">pic.twitter.com/aPbsjXZ2rK</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1877712149432144112?ref_src=twsrc%5Etfw">January 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Prominent technical analyst Kevin <a href="https://x.com/Kev_Capital_TA/status/1877712204121645076">argued</a> that the report&#8217;s strong labor market indicators—low unemployment and PCE inflation within the Federal Reserve's 2% range—are positive for the economy. 
Kevin believes the market&#8217;s negative reaction stems from an overreliance on rate cuts, even though the economy appears healthier without them.
"Report was bullish. Hopefully market comes to its senses," Kevin explained. 
Echoing a similar opinion, Charles Edwards, founder of Capriole Investments highlighted the market&#8217;s bearish overreaction to a strong employment report, which he sees as bullish in the long run.
He noted that fewer jobs would allow rates to stay high, but strong job numbers suggest the bull market could extend further. 
The report, the best in six months, quells fears of rising unemployment. E
dwards also <a href="https://x.com/caprioleio/status/1877720656995135793">pointed</a> out the extremely high intraday put-call ratio, comparable to COVID crash lows, suggesting a potential market bounce ahead.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42919731/bitcoin-to-bounce-back-in-q1-but-beware-20-corrections-analysts-warn">Bitcoin To Bounce Back In Q1 But Beware 20% Corrections, Analysts Warn</a>
Why It Matters: Before the report, analysts outlined <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42909925/previewing-todays-most-important-jobs-report-what-it-means-for-bitcoin">potential market scenarios</a> based on varying unemployment outcomes.
A &#8220;hot&#8221; jobs report—defined as over 200,000 jobs added—was expected to trigger a selloff, which is precisely what happened.
Bitcoin saw whale transactions and exchange netflows dropping by 6.2% and 335%, respectively.
The It is trading at $94,400 at the time of writing, up 1.8% on the day.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42913406/bitcoin-fights-to-regain-94000-what-does-technical-analysis-say">Bitcoin Fights To Regain $94,000: What Does Technical Analysis Say?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Takes 'Stairs Up' And 'Elevator Down' On Labor Market Data: What's Next?

Mizuho analyst Vijay Rakesh maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Outperform and lowers the price target from $85 to $72.

MCHP

Mizuho Maintains Outperform on Microchip Technology, Lowers Price Target to $72

Needham analyst Gil Blum reiterates Immunocore Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) with a Buy and maintains $71 price target.

Reiteration

IMCR

Needham Reiterates Buy on Immunocore Hldgs, Maintains $71 Price Target

Jefferies analyst Stephanie Moore maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and raises the price target from $150 to $165.

Jefferies Maintains Buy on XPO, Raises Price Target to $165

Mizuho analyst Vijay Rakesh maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Outperform and lowers the price target from $95 to $90.

LRCX

Mizuho Maintains Outperform on Lam Research, Lowers Price Target to $90

Shares of social media companies Snap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>), Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) and Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) are trading higher Friday as the U.S. Supreme Court hears oral arguments in the case regarding the <a href="https://www.benzinga.com/25/01/42919029/supreme-court-hears-tiktok-oral-arguments">potential ban of TikTok. </a>
The Details: Oral arguments are underway in the Supreme Court case challenging the pending ban of TikTok. And the Justices appear skeptical of the arguments presented by attorneys for TikTok and its users. 
Chief Justice John Roberts questioned TikTok&#8217;s ties to China and noted that Congress found that ByteDance cooperates with Chinese intelligence work and must comply with China's laws.
Read More: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42900817/quantum-stocks-regetti-computing-ionq-d-wave-poised-to-open-higher-after-nvidia-ceo-comments-drove-huge-losses">Quantum Stocks Regetti Computing, IonQ, D-Wave Poised To Open Higher After Nvidia CEO Comments Drove Huge Losses</a>
"Are we supposed to ignore the fact that the ultimate parent is in fact subject to doing intelligence work for the Chinese government?" Roberts asked.
Justice Brett Kavanaugh defended national security concerns related to data collection through the TikTok app and asked what will occur on the Jan. 19 deadline if the High Court does not act.&nbsp;
Noel Francisco, an attorney representing TikTok, replied that TikTok will &#8220;go dark&#8221; and &#8220;essentially, the platform shuts down.&#8221;&nbsp;
Why It Matters: The case could have implications for the other social media platforms which would most likely benefit from a ban of TikTok. Unless TikTok is sold to a non-Chinese company or the Supreme Court steps in, the platform <a href="https://www.benzinga.com/24/12/42712643/trump-asks-supreme-court-to-delay-tiktok-ban-as-he-pursues-a-political-resolution">will be removed</a> from app stores in the U.S. on Jan. 19. 
What Else: It should also be noted that President-elect Donald Trump was sentenced on Friday <a href="https://www.benzinga.com/news/25/01/42916780/donald-trump-receives-unconditional-discharge-in-new-york-hush-money-case-will-enter-white-house-as-convicted-felon">with an unconditional discharge</a> in the New York hush money case which could also be affecting Trump Media &amp; Technology shares. With the ruling, Trump avoids prison time or probation related to the case. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42899028/la-wildfire-damages-estimated-above-52-billion-california-property-insurance-crisis">LA Wildfire Damages Could Top $52 Billion As California Faces Property Insurance Crisis</a></li>
</ul>
Image: Shutterstock&nbsp;

Large Cap

Social Media

Legal

SNAP

Social Media Stocks Meta, Snap, Trump Media Climb As Supreme Court Hears Arguments On Pending TikTok Ban

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Jason Bazinet initiated coverage on News Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWSA#NASDAQ">NWSA</a>) with a Buy rating and announced a price target of $36. News shares closed at $27.47 on Wednesday. See how other analysts view this stock.</li>
<li>Wells Fargo initiated coverage on Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with an Equal-Weight rating and announced a price target of $47. Maplebear shares closed at $44.82 on Wednesday. See how other analysts view this stock.</li>
<li>UBS analyst Manav Gupta initiated coverage on Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) with a Neutral rating and announced a price target of $62. Tyson Foods shares closed at $55.46 on Wednesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Adam Maeder initiated coverage on ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Neutral rating and announced a price target of $252. ResMed shares closed at $236.17 on Wednesday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Mike Hickey initiated coverage on AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy rating and announced a price target of $375. AppLovin shares closed at $329.20 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying APP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60-1024x591.png" alt="" class="wp-image-728673" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10124356/image-60.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Initiation

CART

NWSA

This AppLovin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Mizuho analyst Vijay Rakesh maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Outperform and lowers the price target from $180 to $160.

Mizuho Maintains Outperform on Advanced Micro Devices, Lowers Price Target to $160

HC Wainwright &amp; Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) with a Buy and maintains $16 price target.

SLDB

HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target

Rumors

BROS

Watching Dutch Bros; Shares See A Pop In Volume To The Upside, Traders Circulate Stock Picked By Investor Business Daily SwingTrader

Mizuho analyst Vijay Rakesh maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Outperform and lowers the price target from $220 to $210.

AMAT

Mizuho Maintains Outperform on Applied Mat, Lowers Price Target to $210

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) with a Buy and maintains $40 price target.

GHRS

HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target

Mizuho analyst Vijay Rakesh maintains Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) with a Outperform and raises the price target from $70 to $85.

CRDO

Mizuho Maintains Outperform on Credo Technology Group, Raises Price Target to $85

Needham analyst Gerald Pascarelli reiterates Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Buy and maintains $280 price target.

Needham Reiterates Buy on Constellation Brands, Maintains $280 Price Target

Stifel

Telsey Advisory Group

Truist Securities

Evercore ISI Group

B of A Securities

Comments

Home Depot

Home Depot (NYSE:HD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga